Publications

391 publications

Enter search criteria

Keyword

Fill in keyword(s) to narrow your search.

Period

Last 7 days Last 30 days Last 365 days Specific period

Period from

The start date was not recognised. Please enter the date in the following format: DD-MM-YYYY.

Period up to

The end date was not recognised. Please enter the date in the following format: DD-MM-YYYY.

The end date may not occur before the start date.

Type

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by:

Date
Relevance

GVS review levomepromazine (Nozinan®) for palliative sedation in a home situation

Zorginstituut Nederland has completed its assessment whether the substance levomepromazine (Nozinan®) can be included in the ...

Report | 29-09-2021
Extension of further conditions for SGLT2 inhibitors following recent GVS advice (22 June 2021)

Zorginstituut Nederland has completed its assessment whether the further conditions of SGLT-2 inhibitors canagliflozin ...

Report | 20-09-2021
GVS advice CGRP inhibitors erenumab, fremanezumab, galcanezumab (Aimovig®, AJOVY®, Emgality®) for the treatment of patients with episodic and chronic migraine

The National Health Care Institute has completed its assessment (using the CBG-ZIN parallel procedure) whether roxadustat ...

Report | 17-09-2021
GVS advice roxadustat (Evrenzo®) for the treatment of symptomatic anaemia in chronic kidney damage

The National Health Care Institute has completed its assessment (using the CBG-ZIN parallel procedure) whether roxadustat ...

Report | 03-09-2021
GVS advice drospirenon-estetrol (Drovelis®)

The National Health Care Institute has completed its assessment whether drospirenon/estetrol (Drovelis®) is interchangeable with ...

Report | 31-08-2021
Follow-up advice on conditional inclusion of larotrectinib (Vitrakvi®)

Zorginstituut Nederland recommends that larotrectinib (Vitrakvi®) should be conditionally included in the basic health care ...

Report | 16-08-2021
Follow-up advice on conditional inclusion of entrectinib (Rozlytrek®)

Zorginstituut Nederland recommends that entrectinib (Rozlytrek®) should be conditionally included in the basic health care ...

Report | 16-08-2021
Package advice ipilimumab (Yervoy®) in combination with nivolumab (Opdivo®)

The National Health Care Institute has completed its assessment whether ipilimumab (Yervoy®) in combination with nivolumab ...

Report | 11-08-2021
GVS advice on the reassessment of tafamidis (Vyndaqel®)

The Zorginstituut recommends not to include tafamidis (Vyndaqel®) in the GVS, unless a price reduction of at least 50% can be ...

Report | 11-08-2021
Advice on the reassessment of axicabtagene ciloleucel (Yescarta®)

The National Health Care Institute has carried out the reassessment of axicabtagene ciloleucel (Yescarta®).

Report | 26-07-2021

Publications

391 publications

GVS review levomepromazine (Nozinan®) for palliative sedation in a home situation

Extension of further conditions for SGLT2 inhibitors following recent GVS advice (22 June 2021)

GVS advice CGRP inhibitors erenumab, fremanezumab, galcanezumab (Aimovig®, AJOVY®, Emgality®) for the treatment of patients with episodic and chronic migraine

GVS advice roxadustat (Evrenzo®) for the treatment of symptomatic anaemia in chronic kidney damage

GVS advice drospirenon-estetrol (Drovelis®)

Follow-up advice on conditional inclusion of larotrectinib (Vitrakvi®)

Follow-up advice on conditional inclusion of entrectinib (Rozlytrek®)

Package advice ipilimumab (Yervoy®) in combination with nivolumab (Opdivo®)

GVS advice on the reassessment of tafamidis (Vyndaqel®)

Advice on the reassessment of axicabtagene ciloleucel (Yescarta®)

Go to